B cells as biomarkers: Predicting immune checkpoint therapy adverse events

Journal of Clinical Investigation

Volumn 128, Issue 2, 2018, Pages 577-579

  Liudahl, Shannon M ^a   Coussens, Lisa M ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC MONOCLONAL ANTIBODY; B LYMPHOCYTE RECEPTOR; BIOLOGICAL MARKER; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR5; COMPLEMENT COMPONENT C3D RECEPTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; IPILIMUMAB; NIVOLUMAB; PROGRAMMED DEATH 1 RECEPTOR; PROGRAMMED DEATH 1 RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

ADVANCED CANCER; ADVERSE EVENT; AUTOIMMUNITY; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL ACTIVATION; CYTOKINE PRODUCTION; DRUG WITHDRAWAL; GENETIC TRANSCRIPTION; HUMAN; IMMUNE RELATED ADVERSE EVENT; IMMUNOPATHOLOGY; LYMPHOCYTE PROLIFERATION; MELANOMA; MEMORY CELL; PATIENT MONITORING; PLASMABLAST; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TREATMENT OUTCOME; TREATMENT RESPONSE; IMMUNOTHERAPY;

AUTOIMMUNITY; B-LYMPHOCYTES; BIOMARKERS; HUMANS; IMMUNOTHERAPY; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 85041476675     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI99036     Document Type: Review

References (25)

1. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27(4):450–461.
2. Wolchok JD, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345–1356.
3. Nishino M, Ramaiya NH, Hatabu H, Hodi FS. Monitoring immune-checkpoint blockade: response evaluation and biomarker development. Nat Rev Clin Oncol. 2017;14(11):655–668.
4. El Osta B, Hu F, Sadek R, Chintalapally R, Tang SC. Not all immune-checkpoint inhibitors are created equal: meta-analysis and systematic review of immune-related adverse events in cancer trials. Crit Rev Oncol Hematol. 2017;119:1–12.
5. De Velasco G, et al. Comprehensive Meta-analysis of key immune-related adverse events from CTLA-4 and PD-1/PD-L1 inhibitors in cancer patients. CancerImmunolRes. 2017;5(4):312–318.
6. Larkin J, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34.
7. Stucci S, et al. Immune-related adverse events during anticancer immunotherapy: pathogenesis and management. OncolLett. 2017;14(5):5671–5680.
8. Horvat TZ, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol. 2015;33(28):3193–3198.
9. Subudhi SK, et al. Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. Proc NatlAcadSciUSA. 2016;113(42):11919–11924.
10. Oh DY, et al. Immune toxicities elicted by CTLA-4 blockade in cancer patients are associated with early diversification of the T-cell repertoire. Cancer Res. 2017;77(6):1322–1330.
11. Das R, et al. Combination therapy with anti- CTLA-4 and anti- PD-1 leads to distinct immunologic changes in vivo. JImmunol. 2015;194(3):950–959.
12. Das R, et al. Early B cell changes predict autoimmunity following combination immune checkpoint blockade. JClinInvest. 2018;128(2):715–720.
13. Teachey DT, et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 2016;6(6):664–679.
14. Hay KA, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood. 2017;130(21):2295–2306.
15. Gürcan HM, Keskin DB, Stern JN, Nitzberg MA, Shekhani H, Ahmed AR. A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol. 2009;9(1):10–25.
16. Miklos D, et al. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood. 2017;130(21):2243–2250.
17. Chiaruttini G, et al. B cells and the humoral response in melanoma: The overlooked players of the tumor microenvironment. Oncoimmunology. 2017;6(4):e1294296.
18. Somasundaram R, et al. Tumor-associated B-cells induce tumor heterogeneity and therapy resistance. Nat Commun. 2017;8(1):607.
19. Affara NI, et al. B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas. Cancer Cell. 2014;25(6):809–821.
20. Shalapour S, et al. Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy. Nature. 2015;521(7550):94–98.
21. Gunderson AJ, et al. Bruton tyrosine kinase-dependent immune cell cross-talk drives pancreas cancer. Cancer Discov. 2016;6(3):270–285.
22. Pylayeva-Gupta Y, et al. IL35-producing B cells promote the development of pancreatic Neoplasia. Cancer Discov. 2016;6(3):247–255.
23. Lee KE, et al. Hif1a deletion reveals pro-neoplastic function of B cells in pancreatic Neoplasia. Cancer Discov. 2016;6(3):256–269.
24. hi identifies a novel regulatory B-cell population in human hepatoma that promotes disease progression. Cancer Discov. 2016;6(5):546–559.
25. + cells dismantle anti-liver cancer immunity. Nature. 2017;551(7680):340–345.